OBJECTIVE: To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta 2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex. DESIGN: Retrospective study of changes in laboratory markers and survival. SETTING: Multicentre trial at university hospital clinics. SUBJECTS: 90 Patients with AIDS or AIDS related complex. INTERVENTION: Patients started zidovudine 200 mg orally every four hours. Fifty six of the patients died a median 17 months after starting zidovudine; the remaining 34 patients were followed up for a median 25.5 months. MAIN OUTCOME MEASURES: Changes in CD4+ lymphocyte count and serum concentrations of p24 antigen and antibody, beta 2 microglobulin, and neopterin; survival of the patient. RESULTS: The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards model: a diagnosis of AIDS (v AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration. When these baseline characteristics were controlled for the logarithm of CD4+ lymphocyte count at weeks 8-12 of treatment (p = 0.007) and an increase in serum beta 2 microglobulin concentration at weeks 8-12 (p = 0.05) also independently correlated with survival. In the 38 patients with a better pretreatment prognosis, 24 month survival estimated by the product-limit method was 88% for those with a good response on both surrogate markers during early treatment compared with only 50% for those with a poor response on either marker. In the 38 with a worse pretreatment prognosis, 24 month survival was estimated to be 49% for those with a good response on both surrogate markers compared with only 18% for those with a poor response on either. CONCLUSION: These data suggest that CD4+ lymphocyte count at 8-12 weeks and, perhaps, change in serum beta 2 microglobulin concentration could be surrogate end points for clinical outcome in trials of antiretroviral drugs for patients with HIV disease.
OBJECTIVE: To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta 2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex. DESIGN: Retrospective study of changes in laboratory markers and survival. SETTING: Multicentre trial at university hospital clinics. SUBJECTS: 90 Patients with AIDS or AIDS related complex. INTERVENTION: Patients started zidovudine 200 mg orally every four hours. Fifty six of the patients died a median 17 months after starting zidovudine; the remaining 34 patients were followed up for a median 25.5 months. MAIN OUTCOME MEASURES: Changes in CD4+ lymphocyte count and serum concentrations of p24 antigen and antibody, beta 2 microglobulin, and neopterin; survival of the patient. RESULTS: The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards model: a diagnosis of AIDS (v AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration. When these baseline characteristics were controlled for the logarithm of CD4+ lymphocyte count at weeks 8-12 of treatment (p = 0.007) and an increase in serum beta 2 microglobulin concentration at weeks 8-12 (p = 0.05) also independently correlated with survival. In the 38 patients with a better pretreatment prognosis, 24 month survival estimated by the product-limit method was 88% for those with a good response on both surrogate markers during early treatment compared with only 50% for those with a poor response on either marker. In the 38 with a worse pretreatment prognosis, 24 month survival was estimated to be 49% for those with a good response on both surrogate markers compared with only 18% for those with a poor response on either. CONCLUSION: These data suggest that CD4+ lymphocyte count at 8-12 weeks and, perhaps, change in serum beta 2 microglobulin concentration could be surrogate end points for clinical outcome in trials of antiretroviral drugs for patients with HIV disease.
Authors: M A Jacobson; D I Abrams; P A Volberding; P Bacchetti; J Wilber; R E Chaisson; S Crowe; W Howard; A Moss Journal: J Infect Dis Date: 1989-06 Impact factor: 5.226
Authors: J J Goedert; C M Kessler; L M Aledort; R J Biggar; W A Andes; G C White; J E Drummond; K Vaidya; D L Mann; M E Eyster Journal: N Engl J Med Date: 1989-10-26 Impact factor: 91.245
Authors: A Krämer; S Z Wiktor; D Fuchs; S Milstien; M H Gail; F J Yellin; R J Biggar; H Wachter; S Kaufman; W A Blattner Journal: J Acquir Immune Defic Syndr (1988) Date: 1989
Authors: M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245
Authors: J P Steinberg; J B Spear; R L Murphy; C B Wallemark; C A Benson; H A Kessler; J C Pottage; J P Phair Journal: J Acquir Immune Defic Syndr (1988) Date: 1989
Authors: J Goudsmit; F de Wolf; D A Paul; L G Epstein; J M Lange; W J Krone; H Speelman; E C Wolters; J Van der Noordaa; J M Oleske Journal: Lancet Date: 1986-07-26 Impact factor: 79.321
Authors: A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson Journal: Br Med J (Clin Res Ed) Date: 1988-03-12
Authors: C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter Journal: J Exp Med Date: 1984-07-01 Impact factor: 14.307
Authors: L Zamora; J M Gatell; J M Barrera; G Ercilla; C Gil; E Buira; J M Miro; E Soriano Journal: Eur J Clin Microbiol Infect Dis Date: 1992-12 Impact factor: 3.267